ARMC9

Across TCGA pan-cancer cohorts, ARMC9 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ARMC9 data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ARMC9 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ARMC9 expression acts as an unfavorable survival marker.

CCRCC, LSCC, and HNSC are the cancer types where ARMC9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	0.128	0.952	.003	29	view →
LSCC	OS	Tertile	II,III,IV	0.749	1.000	.001	26	view →
HNSC	DFS	Median	IV	0.631	0.891	.014	11	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ARMC9–CCRCC (DFS)

Open the CCRCC breakdown →